EverSource Wealth Advisors’s Kymera Therapeutics KYMR Stock Holding History

EverSource Wealth Advisors’s Portfolio KYMR Stock Details KYMR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$28.3K	Buy	247 +23	+10%	+$1.98K	﹤0.01%	2186
2026 Q1	$18.7K	Sell	224 -53	-19%	-$4.2K	﹤0.01%	2542
2025 Q4	$21.6K	Sell	277 -7	-2%	-$473	﹤0.01%	2340
2025 Q3	$16.1K	Buy	284 +9	+3%	+$406	﹤0.01%	2517
2025 Q2	$12K	Sell	275 -153	-36%	-$5.27K	﹤0.01%	2685
2025 Q1	$11.7K	Buy	428 +402	+1,546%	+$14.7K	﹤0.01%	2022
2024 Q4	$1.05K	Buy	26 +14	+117%	+$632	﹤0.01%	2949
2024 Q3	$568	Buy	+12	New	+$530	﹤0.01%	2845

Other funds holding KYMR

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Universal-Beteiligungs- und Servicegesellschaft Frankfurt Am Main, Germany $65.4B AUM 39.83% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Fifth Third Bancorp Cincinnati, Ohio $61.7B AUM 33.76% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return

PCM

Peregrine Capital Management Minneapolis, Minnesota $3.08B AUM 29.51% 1-Year Est. Return

EverSource Wealth Advisors's KYMR Position: Q2 2026 in Review

EverSource Wealth Advisors increased its Kymera Therapeutics (KYMR) stake by 10% in Q2 2026, buying an estimated $1.98K and bringing the position to 247 shares worth $28.3K. The position accounts for ﹤0.01% of the portfolio, ranked #2186.

EverSource Wealth Advisors first reported a position in KYMR in Q3 2024 and has held it in 8 quarters since. 81 funds tracked by Wall St. Rank hold KYMR as of Q2 2026.

EverSource Wealth Advisors held 247 shares of Kymera Therapeutics worth $28.3K as of Q2 2026.
EverSource Wealth Advisors bought 23 Kymera Therapeutics shares in Q2 2026, an estimated $1.98K.
Kymera Therapeutics made up ﹤0.01% of EverSource Wealth Advisors's portfolio in Q2 2026, its #2186 holding.
EverSource Wealth Advisors first reported a position in Kymera Therapeutics in Q3 2024 and has held it in 8 quarters since.
81 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q2 2026.

Based on EverSource Wealth Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.